These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23024015)

  • 1. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
    van der Heijde D; Braun J; Deodhar A; Inman RD; Xu S; Mack ME; Hsu B
    Rheumatology (Oxford); 2013 Feb; 52(2):321-5. PubMed ID: 23024015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
    Kavanaugh A; Mease P
    J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
    Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
    Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    Deodhar A; Braun J; Inman RD; Mack M; Parasuraman S; Buchanan J; Hsu B; Gathany T; van der Heijde D
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1266-71. PubMed ID: 20506403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
    Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
    Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study.
    van der Heijde D; Deodhar A; Inman RD; Braun J; Hsu B; Mack M
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1919-22. PubMed ID: 22740380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
    Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
    Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
    Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of etanercept in enthesitis in ankylosing spondylitis and an evaluation method for enthesitis].
    Zhang J; Huang F; Zhang JL; Zhang H; Zhang YM
    Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):376-9. PubMed ID: 22883337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.
    Tam LS; Shang Q; Kun EW; Lee KL; Yip ML; Li M; Li TK; Zhu TY; Pui MO; Li EK; Yu CM
    Rheumatology (Oxford); 2014 Jun; 53(6):1065-74. PubMed ID: 24501241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
    Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.